From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation [1].
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively [1].
cis-SU4312 ((Z)-SU4312) inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. cis-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively. cis-SU4312 can cross blood brain barrier[1].
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC50 value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC50 of 920 nM [1].
hVEGF-IN-2 (compound 19) is a selective VEGF (Flk-1) receptor tyrosine kinases (RTK) inhibitor with an IC50 value of 2.5 μM. hVEGF-IN-2 inhibits PDGF RTK activity with an IC50 value of 33.1 μM. hVEGF-IN-2 can be used for the development of RTK-specific agents [1].
BMS-605541 is a selective and orally active inhibitor of VEGFR-2 kinase with an IC50 value of 23 nM and Ki value of 49 nM. BMS-605541 inhibits the activity of Flk-1, VEGFR-1 and PDGFR-β with IC50 values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research [1].
Midostaurin-d5 is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].
Midostaurin (Standard) is the analytical standard of Midostaurin. This product is intended for research and analytical applications. Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM [1] . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors [1] .
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors [1] .
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation [1] .
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors [1] .
Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi) is 745 a.a., with molecular weight of 115-140 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc) is 745 a.a., with molecular weight of 135-160 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, mFc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, mFc) is 745 a.a., with molecular weight of 150-200 kDa.
VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. FITC-Labeled VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled VEGFR-2 protein, expressed by HEK293 , with His labeled tag. The total length of FITC-Labeled VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 110-120 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Rhesus macaque (HEK293, His) is 745 a.a., with molecular weight of 115-145 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGFR-2 Protein, Human (745a.a, HEK293, His) is 745 a.a., with molecular weight of ~84.6 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (208a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (208a.a, HEK293, Fc) is 208 a.a., with molecular weight of ~50.4 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (327a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (327a.a, HEK293, Fc) is 327 a.a., with molecular weight of ~61.5 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc) is 743 a.a., with molecular weight of ~138.21 kDa.
VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2. VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis. VEGFR-2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Rat (HEK293, Fc) is 760 a.a., with molecular weight of ~110 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) is 762 a.a., with molecular weight of ~84.5 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is 745 a.a., with molecular weight of 150-160 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Cynomolgus (HEK293, His) is 745 a.a., with molecular weight of ~115-180 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor. As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis. It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization. VEGFR-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Mouse (HEK293, His) is 762 a.a., with molecular weight of 100-110 kDa.
VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2. VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis. VEGFR-2 Protein, Rat (HEK293, His) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Rat (HEK293, His) is 741 a.a., with molecular weight of ~115-180 kDa.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His-Avi) is 745 a.a., with molecular weight of 120-150 kDa.
VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-2 Protein, Human (HEK293, His) is 745 a.a., with molecular weight of 84-140 kDa.
Midostaurin-d5 is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].
Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
VEGF Receptor 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 152 kDa, targeting to VEGF Receptor 2. It can be used for WB,ICC,IHC-P,IP assays with tag free, in the background of Human, Rat.
VEGFR2 Antibody is a biotin-conjugated non-conjugated IgG antibody, targeting VEGFR2, with a predicted molecular weight of 152 kDa. VEGFR2 Antibody (YA1388) can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA experiment in human, mouse background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
